Pertussis cost-effectiveness of therapy

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2] Luke Rusowicz-Orazem, B.S.

Pertussis Microchapters


Patient Information


Historical Perspective



Differentiating Pertussis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies


Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pertussis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Pertussis cost-effectiveness of therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pertussis cost-effectiveness of therapy

CDC onPertussis cost-effectiveness of therapy

Pertussis cost-effectiveness of therapy in the news

Blogs on Pertussis cost-effectiveness of therapy

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Pertussis cost-effectiveness of therapy

Cost Effectiveness of Therapy

  • Given the morbidity of of Pertussis, the cost-effectiveness of treatment is substantial.
    • A retrospective assessment of medical costs of confirmed pertussis in 936 adults in Massachusetts during 1998 to 2000, and a prospective assessment of nonmedical costs in 203 adults during 2001 to 2003 indicated that the mean medical and nonmedical cost per case was $326 and $447, respectively, for a societal cost of $773.[1]
    • If the cost of antimicrobials to treat contacts and the cost of personal time were included, the societal cost could be as high as $1,952 per adult case.[1]

Cost Effectiveness of Vaccination

  • Cost-benefit and cost-effectiveness analyses of adult Tdap vaccination have varied in their results. When discrepancies in the models were addressed, an adult Tdap vaccination program was cost-effective when incidence of pertussis exceeded 120 cases per 100,000 population, using a benchmark of $50,000 per quality-adjusted life year saved. [2]


  1. 1.0 1.1 "National Guideline Clearinghouse | Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP)".
  2. Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S, Lieu TA (2007). "Cost effectiveness of pertussis vaccination in adults". Am J Prev Med. 32 (3): 186–193. doi:10.1016/j.amepre.2006.10.016. PMID 17296470.

Template:WH Template:WS